Evaluating BioNTech SE (NASDAQ: BNTX) involves balancing its robust cash reserves and leadership in mRNA technology against post-pandemic revenue normalization from COVID-19 vaccine sales. While long-term growth investors are attracted to its expanding oncology pipeline, analysts treat it as a high-risk, high-reward bet dependent on upcoming clinical readouts.